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study aimed to perform an importance-performance analysis of prioritized key interventions (KIs) by linking
guideline adherence rates to expert consensus ratings for the management of a DBD.
Materials and methods: This observational, cross-sectional multicenter study was performed in 21 Belgian ICUs.Keywords:Purpose: Guideline adherence for the management of a donor after brain death (DBD) is largely unknown. This
A retrospective review of patient records of adult utilized DBDs between 2013 and 2016 used 67 KIs to describe
adherence to guidelines.
Results: A total of 296 patients were included. Thirty-ﬁve of 67 KIs had a high level of adherence congruent to a
high expert panel rating of importance. Nineteen of 67 KIs had a low level of adherence in spite of a high level of
importance according to expert consensus. However, inadequate documentation proved an important issue,
hampering true guideline adherence assessment. Adherence ranged between 3 and 100% for single KI items
and on average, patients received 72% of the integrated expert panel recommended care set.
Conclusions:Guideline adherence to an expert panel predeﬁned care set inDBDdonormanagement provedmod-
erate leaving substantial room for improvement. An importance-performance analysis can be used to improve
implementation and documentation of guidelines.
© 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Donation after brain death
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For the management of a potential donor after brain death (DBD),
consensus-based guidelines, such as the recommendations of the Soci-
ety of Critical Care Medicine, provide evidence-based advice aiming at
improving quality of care [1]. Guidelines however are not necessarily
implemented in practice [2,3]. A recent systematic review on sustain-
ability of adherence to guidelines by medical professionals identiﬁed aCorneel Heymanslaan 10, 9000
elaers@ugent.be (D. Vogelaers),
te@ugent.be (E. Hoste),
nt.be (K. Eeckloo),
. This is an open access article underlimited number of studies and lack of methodological quality, hamper-
ing conclusions [4].
Compliance to guidelines for potential DBD is largely unknown and
most studies have focused on brain death diagnosis. Adherence to the
American Academy of Neurology (AAN) guidelines for determination
of brain death, updated in 2010, proved variable [5,6]. A study in 91
countries revealed differences in perceptions and practices of brain
death diagnosis worldwide. In comparison to AAN criteria, signiﬁcant
between-hospital variability was documented in examinations, apnea
testing, necessity and type of ancillary testing, time to brain death dec-
laration, as well as the number andminimal qualiﬁcations of physicians
required for declaration [7].
Besides brain death determination, management of a potential DBD
should focus through adherence to guidelines, on different other issues,
includingmaintenance of adequate perfusion to all organ systems, early
referral to the organ procurement organizations, and family support [8].the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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be prioritized in order to guarantee high quality care, and impact signif-
icantly on patient, donor family, recipient or graft outcomes. However,
targeting the right areas for improvement remains difﬁcult. Focusing
on all the KIs as a whole can prove burdensome and complex. An
importance-performance analysis, originally a marketing research
technique, can be an alternative method of prioritizing KIs by linking
KI expert panel ratings of importance to the performance indicator of
guideline adherence rates [9].
Hence, the aim of this study is to perform such an importance-
performance analysis of predeﬁned KIs for themanagement of a poten-
tial DBD by linking guideline adherence rates to expert panel ratings of
importance.
2. Material and methods
2.1. Variables
Selection of KIs was based on existing guidelines [10-19], review ar-
ticles [1,20-26] and process ﬂow diagrams [27-35]. This selection of KIs
was evaluated in a RANDmodiﬁed three-round Delphi study, aiming at
expert consensus on the importance of a KI for themanagement of a po-
tential DBD. Eighteen experts within Belgium rated all the selected KIs
on a 9-point Likert rating scale (score 1 indicating “strongly disagree”;
score 9 “strongly agree”) on the extent of contribution to quality of
care. A KI was considered important with a median score of 7 or more
with 75% or more of the ratings within the highest tertile (Likert
score: 7–9). Out of a total of 80 KIs assessed throughout the Delphi pro-
cess, 54 KIs with consensus and 14 KIs without consensus on impor-
tance after the third Delphi round were included in the importance-
performance analysis. Two KIs without consensus were combined,
achieving a ﬁnal tally of 67 KIs. The KIs were classiﬁed into 4 core pro-
cesses: (I) detection inside the ICU and notiﬁcation to a transplant cen-
ter (10 KIs); (II) donor evaluation and characterization (15 KIs); (III)
donor management, bundled as: general care (7 KIs), monitoring (14
KIs), cardiovascular management (5 KIs), respiratory management (4
KIs), renal and electrolyte management (6 KIs), hormone substitution
(4 KIs); and (IV) post procurement (3 KIs). Twelve KIs were excluded
because of impossibility of objective measurement in patient records
or restriction of implementation to clinical indication [36].
2.2. Study population
This observational, cross-sectional multicenter study was part of the
Care Pathway for Donation after Brain Death (CP4DBD) quality im-
provement research project, set up by the Belgian federal government
to evaluate and improve the care process and quality of care for poten-
tial DBDs (or for the donor family, recipient or graft). All 84 Belgian
acute hospitals with a recognized donor coordination function were in-
vited in June 2016 to participate through an information letter from the
Director General, Department of Healthcare, Federal Public Service
Health, Food Chain Safety and Environment. A local study coordinator
was appointed in each participating hospital.
Patient inclusion criteria for the study consisted of (1) utilized DBD
(actual donor from whom at least one organ was transplanted),
(2) adults (≥18 years of age), and (3) admitted to an intensive care
unit (ICU) between January 1, 2013 and December 31, 2016.
Hospital and ICU characteristics were collected at the start of the
study. Patient characteristics, admission data and adherence to guide-
lines were recorded by retrospective review of in-hospital patient re-
cords, using a standardized data extraction form. Registration of the
variable (KIs) within the patient record was assessed as “performed”,
“not performed” or “notmeasurable” (and in some caseswith not appli-
cable or not possible). Variables were reported as not performed when
the patient record explicitly stated the absence of the intervention. KIs
were reported as not measurable whenever information on (non-)execution of the KI wasmissing or ambiguous. This allowed discrimina-
tion between non-executed and non-documented variables.
2.3. Importance-performance matrix
The relationship between importance and adherence is represented
by an importance-performance matrix, as used in similar research
[37,38]. The KI importance dimension was deﬁned by the expert-
rating described above [36]. The performance dimension was deﬁned
by the adherence rate, measured per KI as the number of patients that
received the KI (numerator)/the number of patients for whom the KI
was indicated (denominator). A cut-off of 75% was deﬁned to represent
a high level of performance. Combining the importance and perfor-
mance dimensions forms a matrix consisting of 4 quadrants [9]. The
upper 2 quadrants represent important KIs, with high adherence
(upper right) and low adherence rate (upper left). The lower 2 quad-
rants represent the less important KIs, with high adherence (lower
right) and low adherence rate (lower left).
2.4. Statistical analysis
Continuous data are reported as mean and standard deviation (SD)
or median and interquartile range (IQR), dichotomous data presented
as absolute numbers and percentage. Analyses at hospital and patient
level were performed in SPSS version 24.0.
2.5. Ethical approval
The study received ethical approval from the Ethical Committee of
the Ghent University Hospital, Belgium (2016/1089, B670201629590)
and from the Ethical Committee of each participating hospital.
3. Results
3.1. Hospital and patient characteristics
Twenty-one Belgian hospitals participated in the study, including 4
(19%) university and 17 (81%) non-university hospitals. Their number
of hospital beds ranged between 235 and 1995. The number of adult
ICU beds which were 24/7 functional for mechanical ventilation ranged
between6 and 94. The average number of patients per hospital included
was 14.1 and ranged between 1 and 41.
Over the 4-year study period from January 1, 2013 to December 31,
2016, data from 296 DBDs (mean age 52.4 ± 16.2 years, 155 (53%)
male) were retrospectively collected. This sample represented 34% of
all DBDs (n = 881) in Belgium in the same time period [39]. The
mean organs transplanted per donor (OTPD) was 3.7 ± 1.7 and 150
(51%) had ≥4 OTPD. Of the 296 ICU admissions, 195 (66%) were trans-
ferred directly from the emergency room of the same hospital and 44
(15%) directly from another hospital. Hospital and patient characteris-
tics are summarized in Table 1.
3.2. Importance-performance analysis
The importance-performance matrix is presented in Fig. 1. Thirty-
ﬁve of the 54 high level of importance KIs had a level of performance
above 75% (upper right quadrant). Nineteen of the 54 high level of im-
portance KIs were performed for b75% of the patients (upper left quad-
rant) and can thus be classiﬁed as high priority interventions to improve
the management of a potential DBD. Eleven of these underused KIs do
not achieve a threshold performance of 50%. In the lower left quadrant,
10 low priority KIs are shown with both low importance and perfor-
mance. Three overused KIs were identiﬁed (lower right quadrant)
with low importance and nevertheless high performance.
Table 1
Hospital and patient characteristics.
Hospital characteristics (n= 21)
Total
Hospital beds, median (IQR) 542 (451–970)
Adult ICU beds, median (IQR) 22 (13–44)
Type of hospital, n/N (%)
University 4/21 (19%)
Non-university 17/21 (81%)
Neurosurgical facilities on site, n/N (%) 21/21 (100%)
Interventional neuroradiology facilities on site, n/N (%) 12/21 (57%)
Transplantation facilities on site, n/N (%) 5/21 (24%)
Number of included patients per hospital, n/N (%)
b5 6/21 (29%)
5–10 4/21 (19%)
11–20 6/21 (29%)
21–30 1/21 (5%)
31–40 3/21 (14%)
41–50 1/21 (5%)
Patient characteristics (n= 296)
Total
Age (in years), mean ± SD 52.4 ± 16.2
Sex, n/N (%)
Male 155/295 (53%)
Female 140/295 (47%)
Unknown 1
Admission source, n/N (%)
Emergency room 195/295 (66%)
Other acute care hospital 44/295 (15%)
Operating room 35/295 (12%)
General ward 19/295 (6%)
Other 2/295 (1%)
Unknown 1
Type of admission, n/N (%)
Medical 145/296 (49%)
Surgical: emergency 90/296 (30%)
Trauma 51/296 (17%)
Surgical: elective 9/296 (3%)
Burns 1/296 (0.3%)
Cause of death
Anoxia/strangulation 6/296 (2%)
Cardiovascular 19/296 (6%)
Cerebral Ischemia 16/296 (5%)
Intracranial bleeding 156/296 (53%)
Suicide 7/296 (2%)
Trauma (other) 51/296 (17%)
Trauma (road accident) 18/296 (6%)
Tumor 5/296 (2%)
Other 18/296 (6%)
Organs transplanted per donor, mean ± SD (n/N) 3.7 ± 1.7 (1106/296)
% used organs of utilized donors after brain death, n/N (%)
Kidney right 235/296 (79%)
Kidney left 234/296 (79%)
Liver 242/296 (82%)
Heart 102/296 (34%)
Lung right 132/296 (45%)
Lung left 133/296 (45%)
Pancreas 25/296 (8%)
Intestine 3/296 (1%)
SD= Standard deviation; IQR = Interquartile range.
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Table 2 summarizes adherence and expert consensus rates for all KIs.
Adherence to individual KIs varied between 100% (blood gas analysis on
a regular basis) and 3% (written reporting of detection of serious ad-
verse events). Furthermore, low adherence to high importance guide-
lines (upper left quadrant in the importance-performance matrix)
(b50% and N N 100) was found for the following interventions:
reviewing, if polyuria, of the medical history, urinary and blood sample
to exclude secondary polyuria (14%); interviewing family and/or other
relevant sources to obtain the medical and behavioral history (23%);information to the family about brain death diagnosis (28%); installa-
tion of lung protective ventilation (41%); oral hygiene every 6 h
(42%); written report of the clinical examination of the potential
donor (48%); and information to the family about the possibility of
organ and tissuedonation and theoutcomeof theNational Register con-
sultation (49%). None of the patients received the full care set of 54 KIs.
On average, patients received 72% of recommended care. For the donor
management care activities, the received recommended care was 86%
for general care (4 KIs), 84% for monitoring (11 KIs), 77% for cardiovas-
cularmanagement (3 KIs), 42% for respiratorymanagement (2KIs), 74%
for renal and electrolytemanagement (5 KIs) and 81% for hormone sub-
stitution (1 KI).
4. Discussion
The present study shows the baseline level of guideline adherence to
a broad set of 67KIs in 21Belgianhospitals and demonstrates signiﬁcant
variability between individual KIs. On average, patients received 72% of
the recommended care set. For the 54 KIs that were rated by experts as
highly important, 35 KIs were performed for N75% of the patients. These
results have no direct benchmark but seem to score better than adher-
ence to recommended care in general, as reported by McGlynn et al.
[3], in which patients received on average 55% of recommended care.
Importance-performance analysis can prove useful to hospitals to
select focused, preferably high level of importance/low level of perfor-
mance, care interventions to improve guideline adherence and docu-
mentation of recommended care, as an alternative to the more
burdensome indiscriminate approach of implementing the whole set
of recommendations. Based on the importance-performance analysis
in the present study, 19 such priority KIs could be identiﬁed. For some
KIs the low performance rate is likely related to under documentation.
Apart from the impact of under documentation on determining true
guideline adherence, documentation shortages as such may represent
a quality problem in daily practice for any complex care process, in
terms of coordination and continuity of care. When an intervention is
not mentioned in the patient record, other healthcare providers are
not aware of its performance, possibly leading to duplication of
interventions.
Notiﬁcation of the local donor coordinator at the time a potential
DBD is detected based on deﬁned clinical triggers is a high level of im-
portance KI but had a performance of only 50%. However, due to inade-
quate documentation in up to 50% of patients, true guideline adherence
is unknown. Nowadays, in many European Union member states in-
cluding Belgium, donor coordinators have been appointed in hospitals
with an intensive care unit, where organ retrieval fromdeceased donors
can be considered. Donor coordinators have clearly deﬁned responsibil-
ities in establishing, managing and reviewing the deceased donation
processes in their hospital [40]. A recent Spanish audit of the donation
pathway of 1970 patients with devastating brain injury, showed that
therewas less family objection to organ donationwhen the donor coor-
dinator participated in the interview [41]. Three consensus KIs related
to the approach of the donor families, e.g., (a) bad news conversation
and support, (b) information about the diagnosis of brain death, and
(c) information about the possibility of organ and tissue donation and
the outcome of the National Register consultation had a performance
of, respectively, 58%, 28% and 49%. However, due to inadequate docu-
mentation of these three KIs in the patient records, respectively, 41%,
72%, 51%, true guideline adherence again could not be certiﬁed. Further
efforts should also focus on implementation strategies in donor hospi-
tals to improve quality of KI documentation. These speciﬁc KIs should
be priorities as it is well recognized that the approach and skills of
health professionals discussing organ donation are key inﬂuences on
decisions made by families regarding organ donation [42].
To obtain an accurate, reliable and objective medical and behavioral
history, health care professionals should perform an interviewwith the
relatives and/or other relevant sources. In our study, the performance
Fig. 1. Importance-performance analysis. The numbers in Fig. 1 correspondwith the key interventionsmentioned in Table 2. The horizontal line shows the high or low level of importance
(75%), whilst the vertical line shows the high or low level of performance (75%). Upper right quadrant: good performance of high priority key interventions; upper left quadrant: bad
performance of high priority key interventions; lower left quadrant: good performance of low priority key interventions; lower right quadrant: bad performance of low priority key
interventions.
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to donor evaluation tominimize any risks associatedwith the transmis-
sion of diseases, together with a detailed review of the medical records,
assessment of the medical and behavioral history, full clinical examina-
tion, ﬁndings of post-mortem autopsy, if performed, and laboratory
tests [40]. However, due to inadequate documentation in up to 75% of
patients, true guideline adherence is unknown. Another priority in
donor evaluation should be the performance of the documentation of
a clinical examination of the potential donor, as only 48% of the patients
received this consensus KI. In our study, the performance rate of a bron-
choscopy in the assessment of lung explantation was 42%, to collect
samples for microbiological tests 31%, and to perform a bilateral bron-
choalveolar lavage to clear mucous plugs or blood clots that may con-
tribute to impaired oxygenation 14%. Transplant centers should
primarily focus on these KIs, related to bronchoscopy, because these
KIs are only performed on their request prior to referral.
Traditionally, normothermic body temperature, which may require
active warming, is aimed for in DBDs. In our study two KIs, monitoring
of central (“core”) body temperature and using of warming mattress,
blankets or warmed intravenous if hypothermia (temperature b 35
°C) had a performance of 70% and 64%, respectively. However, mild hy-
pothermia (34 to 35 °C) after declaration of death according to neuro-
logic criteria may lead to better allograft outcomes. In a comparison of
two targeted temperature ranges (34 to 35 °C and 36.5 to 37.5 °C), hy-
pothermia reduced the frequency of delayed graft function in kidney
transplantation, deﬁned as a requirement for dialysis during the ﬁrst
week after transplantation [43]. Further research is needed to deter-
mine the utility of hypothermia in this setting. Other monitoring prior-
ities include a new 12 lead ECG for a potential heart donor in responseto changes in monitored complexes (performance rate: 40%), bronchial
secretion sample for microscopy and culture if secretions are present
(performance rate: 69%), and hourly monitoring of urine output, for
early detection of diabetes insipidus (performance rate: 53%).
In the absence of literature speciﬁc to DBD, recent guidelines have
recommended to follow established advanced cardiopulmonary life
support guidelines tomanage arrhythmias. In particular, changes in ad-
renergic responses in the course of brain death predispose the potential
DBD to a myriad of transient and sustained arrhythmias requiringmed-
ical management [1]. In our study, 28% of the DBDs had a tachycardia,
but only 45% of these patients received treatment.
As a priority, respiratory management consists of the implementa-
tion of ventilator strategies utilizing low stretch protocols andmeasures
to recruit atelectatic lung to enhance lung recovery [1,23,44]. The mean
performance rate of a lung protective ventilation strategy in our study
was 41%, with a performance rate of 36% for a minimum FiO2 to obtain
a PaO2 between 80 and 100 mmHg, 45% for a tidal volume between 6
and 8mL/kg, 67% for a plateau pressure b 30 cmH2O, and 17% for a pos-
itive end expiratory pressure between 8 and 10 cm H2O. Besides, Hua
et al. recently concluded in a systematic review that oral hygiene care
reduces the risk of developing ventilator-associated pneumonia from
25% to about 19%. In our study, the performance rate for oral hygiene
care every 6 h was 42%, demonstrating once again room for improve-
ment [45].
In our study, 43% of the patients had diabetes insipidus. The perfor-
mance rate to review the medical history, urinary and blood sample to
exclude secondary polyuria (osmotic, induced or adapted) was respec-
tively 14%, undoubtedly an underestimation of true guideline adher-
ence in view of inadequate documentation in up to 85% of cases.
Table 2
Adherence to the key interventions for the management of a potential donor after brain death.
Number Intervention Performance
rate n/N (%)
Not documented
n/N (%)
Expert consensus
rate (%) [36]
Detection inside the ICU and notiﬁcation to a transplant center
1 Detection of the potential donor after brain death based on deﬁned clinical
triggers.
241/296 (81%) 52/296 (18%) 100%
2 Notiﬁcation to the local donor coordinator at the time these criteria are met. 147/296 (50%) 148/296 (50%) 94%
3 Assessment of the prerequisites prior to the clinical evaluation of brain death. 1871/2087 (90%) a 20/2087 (1%) a 89%
a) Coma, irreversible, and cause known. 261/261 (100%) 0/261 (0%)
b) Neuroimaging compatible with coma. 258/261 (99%) 0/261 (0%)
c) Central nervous system depressant drug effect absent (if indicated, toxi-
cology screen; if barbiturates given, serum level b 10 μg/mL).
249/261 (95%) 4/261 (2%)
d) No evidence of residual paralytics or neuromuscular blocking agents
(electrical stimulation if paralytics used).
257/261 (98%) 3/261 (1%)
e) Absence of severe acid-base, electrolyte, and endocrine abnormality. 217/261 (83%) 1/261 (0.4%)
f) Normothermia or mild hypothermia (core temperature N 36 °C). 155/261 (59%) 1/261 (0.4%)
g) Systolic blood pressure N 100 mmHg. Vasopressors may be required. 224/261 (86%) 1/261 (0.4%)
h) No spontaneous respiration. 250/260 (96%) 10/260 (4%)
4 Family approach (bad news conversation and support). 341/586 (58%) b 243/586 (41%) b 100%
a) Delivering bad news about the hopeless, medical situation. 198/293 (68%) 95/293 (32%)
b) Support of the family (physician, nurse, social assistant, psychologist, pas-
toral service…).
143/293 (49%) 148/293 (51%)
5 Notiﬁcation of the potential donor after brain death by an ICU physician to a
transplant center.
290/296 (98%) 6/296 (2%) 89%
6 Determination of brain death 808/888 (91%) c 75/888 (8%) c 100%
a) According to the latest medical knowledge concerning the subject. 260/296 (88%) 32/296 (11%)
b) By three physicians. 274/296 (93%) 21/296 (7%)
c) Excluding those who are treating the receptor or will perform the pro-
curement or transplantation.
274/296 (93%) 22/296 (7%)
7 Legal declaration of death. 241/296 (81%) 31/296 (10%) 89%
8 Notiﬁcation to the legal authorities if the cause of death was unknown or
suspicious.
72/79 (91%) 7/79 (9%) 89%
9 Information to the family about the diagnosis of brain death. 81/294 (28%) 213/294 (72%) 100%
10 Information to the family about the possibility of organ and tissue donation
and the outcome of the National Register.
286/586 (49%) d 298/586 (51%) d 94%
a) Information to the family about the possibility of organ and tissue
donation.
271/294 (92%) 23/294 (8%)
b) Information to the family about the outcome of the National Register. 15/292 (5%) 275/292 (94%)
c) Preferably in a separated conversation after family understand the diag-
nosis of brain death.
34/294 (12%) 258/294 (88%)
d) Preferably in a separated conversation after family accept the diagnosis of
brain death.
33/294 (11%) 259/294 (88%)
Donor evaluation and characterization
11 Interviewing family and/or other relevant sources to obtain the medical and
behavioral history.
68/296 (23%) 223/296 (75%) 89%
12 Reviewing medical charts to obtain the medical and behavioral history. 267/296 (90%) 27/296 (9%) 89%
13 Clinical examination of the potential donor: written report. 142/296 (48%) 23/296 (8%) 89%
14 Blood sample. 292/296 (99%) 4/296 (1%) 100%
15 ABO and rhesus blood group or additional laboratory tests. 563/592 (95%) e 3/592 (1%) e 83%
a) ABO and rhesus blood group. 273/296 (92%) 3/296 (1%)
b) Additional laboratory tests. 290/296 (98%) 0/296 (0%)
16 Urine sample: measurement of sediment, protein & glucose. 283/296 (96%) 4/296 (1%) 83%
17 Chest X-ray: mandatory for each potential donor and to allow evaluation of a
potential lung and/or heart donor.
293/296 (99%) 0/296 (0%) 89%
18 Bronchoscopy (on request of the transplant center, all the following
interventions are not always necessary)
114/393 (29%) f 23/393 (6%) f 78%
a) To allow evaluation of a potential lung donor. 57/135 (42%) 7/135 (5%)
b) To collect samples for microbiological tests. 39/127 (31%) 6/127 (5%)
c) To perform a bilateral bronchoalveolar lavage (BAL) to clear mucous plugs
or blood clots that may contribute to impaired oxygenation.
18/131 (14%) 10/131 (8%)
19 Arterial blood gas: to allow evaluation of a potential (lung) donor. 134/135 (99%) 1/135 (1%) 83%
20 Arterial blood gas after 10 min ventilation with FiO2 100% & 5 cm H2O PEEP: to
allow evaluation of a potential lung donor.
133/135 (99%) 0/135 (0%) 83%
21 12 lead ECG: to allow (partial/initial) evaluation of a potential heart donor. 95/101 (94%) 1/101 (1%) 89%
22 Cardiac ultrasound: to allow evaluation of a potential heart donor. 99/102 (97%) 0/102 (0%) 89%
23 Coronary angiography: if cardiac ultrasound is acceptable but other
comorbidities are present.
26/33 (79%) 1/33 (3%) 89%
24 Abdominal ultrasound (or CT scan): to allow evaluation of a potential liver,
pancreas and/or kidney donor.
287/291 (99%) 1/291 (0%) 94%
25 Collection of the minimum data on a donor information form as requested by
the transplant center for the characterization of organs and donor.
265/296 (90%) 26/296 (9%) 100%
Donor management: general care
26 Presence of an arterial and central venous line. 277/296 (94%) 1/296 (0.3%) 83%
27 Continuation of appropriate antibiotic therapy and other life supporting
pharmacotherapy.
290/296 (98%) 0/296 (0%) 94%
28 Continuation of enteral feeding (until otherwise instructed by the transplant 11/26 (42%) 0/26 (0%) 56%
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Table 2 (continued)
Number Intervention Performance
rate n/N (%)
Not documented
n/N (%)
Expert consensus
rate (%) [36]
center).
29 Continuation of deep venous thrombosis prophylaxis if there were no
contraindications.
73/107 (68%) 1/107 (1%) 72%
30 Prescription of low-dose dopamine with a dose of (and not exceeding) 4
μg/kg/min until the aortic clamping.
48/296 (16%) 1/296 (0.3%) 39%
Halving the dosage or ending the infusion when circulatory adverse effects
occurred in association with the dopamine infusion, such as tachycardia or a
marked increase in blood pressure.
15/32 (47%) 0/32 (0%)
31 Prevention of hypothermia. 93/146 (64%) 28/146 (19%) 78%
32 Reduction of the vasopressor dose to the minimal level to maintain
hemodynamic stability.
238/263 (90%) 1/263 (0.4%) 100%
Donor management: monitoring
33 Monitoring of the core body temperature. 207/296 (70%) 58/296 (20%) 100%
34 ECG monitoring of heart rate. 296/296 (100%) 0/296 (0%) 78%
35 New 12 lead ECG for a potential heart donor if there are subsequent changes in
monitored complexes.
6/15 (40%) 1/15 (7%) 83%
36 Invasive arterial pressure monitoring. 294/296 (99%) 1/296 (0.3%) 94%
37 Measurement of additional parameters with extended monitoring (e.g. PICCO,
pulmonary artery catheter…) in case of a patient with hemodynamic
instability.
14/68 (21%) 0/68 (0%) 53% g
38 Availability of a recent chest X-ray for a potential lung and/or heart donor. 174/176 (99%) 0/176 (0%) 89%
39 Monitoring of ventilator parameters. 287/296 (97%) 6/296 (2%) 94%
40 Assessment of cuff pressure, periodically, to check if there is no cuff leak and
cuff pressure is 20–30 cm H2O to avoid aspiration.
216/296 (73%) 35/296 (12%) 67%
41 Peripheral oxygen saturation monitoring. 296/296 (100%) 0/296 (0%) 83%
42 Blood gas analysis on a regular basis. 296/296 (100%) 0/296 (0%) 89%
43 Bronchial secretion sample for microscopy and culture if secretions are
present.
167/242 (69%) 25/242 (10%) 89%
44 Monitoring of urine output (hourly). 157/296 (53%) 1/296 (0%) 89%
45 Measurement of blood electrolytes on a regular basis. 296/296 (100%) 0/296 (0%) 89%
46 Monitoring of glycemic status. 296/296 (100%) 0/296 (0%) 72%
Donor management: cardiovascular management
47 Treatment of hypertension related to “adrenergic storm” of severe degree
(MAP N120 mmHg) and prolonged (N 30 to 60 min) with calcium entry
blockers or short-acting cardioselective beta-blockers.
53/89 (60%) 0/89 (0%) 67%
48 No prescription of hydroxyethyl starch (HES) for intravascular volume
replacement.
247/279 (89%) 1/279 (0.4%) 72%
49 Prescription of vasoactive drugs when correction of the volume deﬁcit fails to
achieve the threshold hemodynamic goals.
263/265 (99%) 0/265 (0%) 100%
50 Treatment of bradycardia causing hemodynamic instability with a short acting
β-adrenergic agonist (epinephrine/dopamine/dobutamine/isoprenaline) or
occasionally transvenous pacing.
6/7 (86%) 0/7 (0%) 83%
51 Treatment of tachycardia. 38/83 (46%) 0/83 (0%) 89%
Donor management: respiratory management
52 Installation of a lung protective ventilation. 491/1184 (41%) h 148/1184 (13%) h 89%
a) Minimum FiO2 to obtain a PaO2 between 80 and 100 mmHg. 107/296 (36%) 1/296 (0.3%)
b) Tidal volume (Vt): 6–8 mL/kg (ideal body weight). 134/296 (45%) 45/296 (15%)
c) Plateau pressure: b 30 cm H2O. 199/296 (67%) 93/296 (31%)
d) PEEP (Positive End Expiratory Pressure): 8–10 cm H2O. 51/296 (17%) 9/296 (3%)
53 Intermittent nasopharyngeal suction. 235/296 (79%) 42/296 (14%) 67%
54 Intermittent tracheal suction. 211/296 (71%) 44/296 (15%) 67%
55 Oral hygiene every 6 h. 125/296 (42%) 29/296 (10%) 89%
Donor management: renal and electrolyte management
56 If oliguria, no prescription of diuretic after treating of hypovolemia,
hypotension and cardiac dysfunction.
83/92 (90%) 1/295 (0.3%) 100%
57 If diabetes insipidus, reviewing of the medical history, urinary and blood
sample to exclude secondary polyuria.
18/130 (14%) 111/130 (85%) 100%
58 If diabetes insipidus, adequate diagnose of diabetes insipidus. 115/131 (88%) 1/131 (1%) 94%
59 If diabetes insipidus, treatment of diabetes insipidus with sufﬁcient ﬂuid
volume replacement to compensate polyuria and anti-diuretic hormone
replacement.
110/127 (87%) 0/127 (0%) 100%
60 Treatment of electrolyte disturbances. 176/191 (92%) 1/191 (1%) 100%
Donor management: hormone substitution
61 Prescription of hydrocortisone to reduce the cumulative dose and
administration duration of vasopressors.
60/267 (22%) 1/267 (0.4%) 17%
62 Appropriate prescription of insulin if treating hyperglycemia to achieve a
target glucose level of 180 mg/dL or less.
187/230 (81%) 0/230 (0%) 83%
63 Prescription of methylprednisolone (250 mg bolus +100 mg/h until recovery
of organs) for a potential liver donor.
63/242 (26%) 0/242 (0%) 33%
64 Thyroid replacement therapy for hemodynamically unstable donors or for
potential hearts donors with abnormal (b45%) left ventricular ejection
fraction.
12/19 (63%) 2/19 (11%) 39%
(continued on next page)
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Table 2 (continued)
Number Intervention Performance
rate n/N (%)
Not documented
n/N (%)
Expert consensus
rate (%) [36]
Post procurement
65 Written report that detection of serious adverse events was performed. 10/296 (3%) 19/296 (6%) 100%
If a serious adverse event was detected, registration and reporting to the
transplant center.
5/6 (83%) 1/6 (17%)
66 Debrieﬁng about the results of the transplantation. 663/1167 (57%) i 361/1167 (31%) i 94%
a) The relatives 182/283 (64%) 96/283 (34%)
b) The health care professionals 178/296 (60%) 96/296 (32%)
c) The primary care physician 98/296 (70%) 82/296 (28%)
67 Exclusion of any medical, pharmaceutical or hospital costs after the
determination of brain death and legal declaration of death on the
hospitalization invoice.
217/296 (73%) 27//296 (9%) 94%
a 3 = 3a + 3b + 3c + 3d + 3e + 3f + 3 g + 3 h.
b 4 = 4a + 4b.
c 6 = 6a + 6b + 6c.
d 10 = 10a + 10b.
e 15 = 15a + 15b.
f 18 = 18a + 18b + 18c.
g Mean results of 2 key interventions.
h 52 = 52a + 52b + 52c + 52d.
i 66 = 66a + 66b + 66c.
62 P. Hoste et al. / Journal of Critical Care 49 (2019) 56–63To conclude, three post procurement KIs should be prioritized based
on our importance-performance analysis. These interventions are ex-
pected to fall under the responsibility of a well-trained donor coordina-
tor on the ICU. The performance rate of a written report on detection of
serious adverse events was only 3%, debrieﬁng about the results of the
transplantation to the relatives, health care professionals and primary
care physician 57%, and ensuring that the hospitalization invoice of
the patient is excluded of any medical, pharmaceutical or hospital
costs after the determination of brain death and legal declaration of
death 73%.
A ﬁrst limitation of the study consists of possible selection bias, as
only the utilized DBDs are included. Hospitals without utilized but
with potential DBDs could not participate in the study. Besides, poten-
tial DBDs lost along the organ donation pathway were not included in
the dataset, but could also provide useful information. Resource and
time constraints excluded a detailed chart reviewof all deceased ICU pa-
tients in participating hospitals. Second, an inclusion criterion on hospi-
tal level to participate in the study was the willingness to develop and
implement a care pathway for donation after brain death after the
study. This may bias selection of participating hospitals towards those
with already present intrinsic motivation towards standardizing care
andmanagement of potential DBD. A ﬁnal andmajor limitation consists
of the frequent underestimation of the true guideline adherence as anal-
ysis was restricted to information available in the patient records with
obvious suboptimal clinical documentation. This however can be con-
sidered as a major ﬁnding in itself.
To our knowledge, this is the ﬁrst audit evaluating clinical practice in
the entire donation pathway. The main novelty resides in the use of an
importance-performance analysis as an approach for prioritizing inter-
ventions in improving quality of care for potential DBDs. The participat-
ing hospitals in this CP4DBD quality improvement research project
received a detailed report with the guidelines upon which these KIs
were based, together with feedback on actual organization of the care
process. In addition, all participating hospitals received training on
care pathway development and implementation. An evidence-based
care pathway and this benchmarking approach in donor hospitals can
be used as amethod to reduce clinical variability and improve both doc-
umentation as well as adherence [46-48]. Documentation, monitoring,
and evaluation of variances and outcomes are one of the essential com-
ponents of a care pathway [49]. The introduction of a checklist can be a
useful tool to support this and to address the proven documentation
need in the donation pathway. Growing evidence in several areas of
healthcare has supported the introduction of such tools in clinical prac-
tice [50-52].In conclusion, guideline adherence to an expert panel predeﬁned
care set in DBD donor management proved moderate with substantial
room for improvement. These ﬁndings underscore the need for a strat-
egy to improve implementation and documentation of evidence-based
guidelines, for which an importance-performance analysis may prove
useful.
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